Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
10
|
pubmed:dateCreated |
1990-1-23
|
pubmed:abstractText |
Brequinar, DUP 785, is a substituted 4-quinoline carboxylic acid derivative which in preclinical studies has shown broad antitumor activity. It is a novel antimetabolite blocking pyrimidine nucleotide synthesis. In a clinical phase I study, 83 patients were treated on a weekly schedule and 18 patients on a biweekly schedule. The drug was given intravenously as a short infusion. Three patients were entered on each dose level from a starting dose of 6 mg/m2 up to 2600 mg/m2 weekly. The dose ranges on a biweekly schedule were 500-850 mg/m2. There was no dose escalation in individual patients. Pharmacokinetic studies were performed in 19 patients on a weekly schedule and in two patients on a biweekly schedule. A biphasic decay in plasma was observed with a median half life of 10 h (5.1-23.4). The main dose-limiting toxicity was thrombocytopenia. Of non-hematologic side-effects, stomatitis/mucositis occurred frequently. Skin eruptions occurred rarely, but were a major problem when found. All side-effects were fully reversible; there were no signs of cumulative toxicity. Antitumor activity was observed in one patient with a lung metastasis from a bladder cancer and in a patient with an unknown primary tumor. The recommended doses for phase II trials with DUP 785 are: 1500-2000 mg/m2 on a weekly schedule and 500-750 mg/m2 on a biweekly schedule dependent on status before treatment.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Oct
|
pubmed:issn |
0277-5379
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
25
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1403-11
|
pubmed:dateRevised |
2004-11-17
|
pubmed:meshHeading |
pubmed-meshheading:2591433-Adolescent,
pubmed-meshheading:2591433-Adult,
pubmed-meshheading:2591433-Aged,
pubmed-meshheading:2591433-Antineoplastic Agents,
pubmed-meshheading:2591433-Biphenyl Compounds,
pubmed-meshheading:2591433-Drug Administration Schedule,
pubmed-meshheading:2591433-Drug Evaluation,
pubmed-meshheading:2591433-Female,
pubmed-meshheading:2591433-Genital Neoplasms, Female,
pubmed-meshheading:2591433-Humans,
pubmed-meshheading:2591433-Lung Neoplasms,
pubmed-meshheading:2591433-Male,
pubmed-meshheading:2591433-Middle Aged,
pubmed-meshheading:2591433-Neoplasms,
pubmed-meshheading:2591433-Platelet Count,
pubmed-meshheading:2591433-Urologic Neoplasms
|
pubmed:year |
1989
|
pubmed:articleTitle |
A phase I clinical and pharmacokinetic study of Brequinar sodium, DUP 785 (NSC 368390), using a weekly and a biweekly schedule.
|
pubmed:affiliation |
Department of Oncology ONB, Finsen Institute, Copenhagen, Denmark.
|
pubmed:publicationType |
Journal Article
|